ArticleEuropean journal of gastroenterology & hepatology2026
Disease burden, diagnosis pathways and treatment patterns in patients with eosinophilic esophagitis: a real-world study.
Article in European journal of gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Time Trends and Impact on Treatment Outcomes of Psychiatric Diagnoses in Patients with Eosinophilic Esophagitis.Journal of gastrointestinal and liver diseases : JGLD · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite a rising prevalence of eosinophilic esophagitis (EoE), real-world data on current management challenges remain limited.
objectiveTo evaluate demographic and clinical characteristics, treatment patterns, and health outcomes in patients with EoE.
methodsPhysicians from Canada, France, Germany, Spain, and the UK retrospectively reviewed records of patients (aged ≥12 years) who were newly diagnosed with EoE between January 2009 and December 2019. EoE diagnosis was confirmed by esophageal biopsy demonstrating a peak eosinophil count ≥15 eosinophils/high-power field (eos/hpf) within 90 days before or after the documented diagnosis (index). Included patients had ≥1 follow-up endoscopy with biopsy and known eosinophil count within 24 months. Data on demographics, clinical characteristics, treatment, and health outcomes were collected 12-month preindex to the last record entry/death.
resultsOverall, 415 patients [mean age (SD): 31.8 (14.6) years] were included. The mean (SD) diagnostic delay from symptom onset was 3.4 (4.8) years [median (range): 1.7 (0.7-4.0)]. The average eosinophil count was 41.4 eos/hpf; 80.2% of patients had endoscopic abnormalities of the esophagus at diagnosis. Post-EoE diagnosis, 77.1% of patients received proton-pump inhibitors, 68.2% swallowed topical corticosteroids, 48.4% made dietary modifications, and 18.8% had esophageal dilation. At diagnosis, 74.5% of patients had dysphagia and 46.0% had heartburn. After diagnosis, 63.5%, 62.2%, and 57.6% did not achieve histologic remission (<15 eos/hpf) at the first, second, and third endoscopy, respectively.
conclusionPatients with EoE experience a substantial disease burden, with a significant delay in diagnosis. Achieving optimal disease control remains an unmet need with conventional nonbiologic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.